Nothing Special   »   [go: up one dir, main page]

MA50474A - Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 - Google Patents

Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1

Info

Publication number
MA50474A
MA50474A MA050474A MA50474A MA50474A MA 50474 A MA50474 A MA 50474A MA 050474 A MA050474 A MA 050474A MA 50474 A MA50474 A MA 50474A MA 50474 A MA50474 A MA 50474A
Authority
MA
Morocco
Prior art keywords
glp
agonists
receptor
long
acting glucagon
Prior art date
Application number
MA050474A
Other languages
English (en)
Inventor
Elisabetta Bianchi
Qiaolin Deng
Chunhui Huang
Federica Orvieto
Anandan Palani
Yuping Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA50474A publication Critical patent/MA50474A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA050474A 2017-09-25 2018-09-21 Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 MA50474A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25

Publications (1)

Publication Number Publication Date
MA50474A true MA50474A (fr) 2020-09-02

Family

ID=65810991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050474A MA50474A (fr) 2017-09-25 2018-09-21 Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1

Country Status (11)

Country Link
US (1) US11566057B2 (fr)
EP (1) EP3700550A4 (fr)
JP (3) JP2020535138A (fr)
KR (1) KR102505628B1 (fr)
CN (1) CN111132690A (fr)
AU (1) AU2018338184B2 (fr)
BR (1) BR112020005841A8 (fr)
CA (2) CA3076496A1 (fr)
MA (1) MA50474A (fr)
MX (1) MX2020003217A (fr)
WO (1) WO2019060660A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842060A1 (fr) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1
WO2022159395A1 (fr) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
MX2024001276A (es) * 2021-07-30 2024-02-15 Boehringer Ingelheim Int Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada.
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
GB0308801D0 (en) * 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
ES2385093T3 (es) 2005-06-13 2012-07-18 Imperial Innovations Limited Análogos de oxintomodulina y sus efectos sobre el comportamiento de la conducta alimentaria
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CA2728284C (fr) 2008-06-17 2019-09-10 Richard D. Dimarchi Co-agonistes du recepteur glucagon/glp-1
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
EP2723367B1 (fr) 2011-06-22 2017-05-03 Indiana University Research and Technology Corporation Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
TN2017000148A1 (en) * 2014-10-24 2018-10-19 Merck Sharp & Dohme Co-agonists of the glucagon and glp-1 receptors
EP3377521A4 (fr) * 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1
WO2017160669A1 (fr) 2016-03-18 2017-09-21 Merck Sharp & Dohme Corp. Conjugués d'insuline-incrétine

Also Published As

Publication number Publication date
EP3700550A4 (fr) 2022-02-23
JP2023171744A (ja) 2023-12-05
CA3220650A1 (fr) 2019-03-28
US20200270325A1 (en) 2020-08-27
CA3076496A1 (fr) 2019-03-28
JP2023071869A (ja) 2023-05-23
BR112020005841A8 (pt) 2023-04-11
RU2020114220A (ru) 2021-10-27
AU2018338184A1 (en) 2020-03-12
WO2019060660A1 (fr) 2019-03-28
KR102505628B1 (ko) 2023-03-02
CN111132690A (zh) 2020-05-08
JP2020535138A (ja) 2020-12-03
EP3700550A1 (fr) 2020-09-02
KR20200057059A (ko) 2020-05-25
MX2020003217A (es) 2020-07-29
US11566057B2 (en) 2023-01-31
RU2020114220A3 (fr) 2021-12-28
AU2018338184B2 (en) 2023-04-13
BR112020005841A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
MA55068A (fr) Co-agonistes des récepteurs du glucagon et du glp-1
MA50474A (fr) Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
DK3555064T5 (da) GLP-1 receptoragonister og anvendelser deraf
DK3806855T5 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
IL285231A (en) Co-agonistic compounds for glucagon and glp-1
FR23C1006I1 (fr) Composés co-agonistes de gip et de glp-1
EP3398961A4 (fr) Triple activateur activant le récepteur du glucagon, du glp-1 et du gip
DK3517538T3 (da) Pyrazolopyridin-derivat med GLP-1-receptoragonistvirkning
DK3551221T3 (da) Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
IL272232A (en) Glp-1 compositions and uses thereof
DK3322437T3 (da) Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
DK3126381T4 (da) Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
EP3377521A4 (fr) Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1
EP3394091A4 (fr) Co-agonistes des récepteurs de glucagon et de glp-1
DK3097313T3 (da) Skrue, fastgørelsesanordning og anvendelse af en skrue
DK3406264T3 (da) Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf
DK3277278T3 (da) Kombinationsdoseringsform af en my-opioid receptorantagonist og et opioid
MA52882A (fr) Agonistes du récepteur glp-1 et leurs utilisations
DK3824614T3 (da) Personlig afskærmningsindretning